Lung cancer
Education on lung cancer prevention searches and Mark Egly research hypotheses about Alpha-1 Antitrypsin biology. Not medical advice.
Research status: Investigational / hypothesis
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. Connections between lung cancer and Alpha-1 Antitrypsin described here reflect Mark Egly's research framing and patent discussion of cancer biology. They are not established medical fact and are not medical advice. Always work with your oncology and pulmonary teams.
What is lung cancer?
Lung cancer is abnormal growth of cells in the lung. Non-small cell lung cancer (NSCLC) is the most common group. Smoking remains the leading risk factor. Screening and treatment follow oncology guidelines from organizations such as the National Cancer Institute and specialty societies.
The Mark Egly Foundation does not provide cancer care. We educate about Alpha-1 Antitrypsin Deficiency (AATD) and research questions that may intersect inflammation and tissue protection.
Lung cancer prevention searches
People often search for lung cancer prevention, smoking cessation, screening eligibility, and environmental risks. Those established prevention topics belong with public health and oncology resources. Our contribution is a research lens on whether Alpha-1 Antitrypsin (AAT) biology relates to inflammation pathways discussed in cancer research.
How this may relate to Alpha-1 (hypothesis)
AAT protects tissues from neutrophil elastase. Mark Egly's patent explores whether low circulating AAT and excess neutrophil activity could influence tumor related biology across several cancers. That proposal is a research hypothesis, not a proven prevention or treatment path for lung cancer.
Separately, AATD is an established cause of emphysema and COPD. People with AATD still need standard smoking cessation support and clinician guided lung care. See COPD and emphysema.
Sibling and hub pages
- AATD and cancer prevention research
- Breast cancer and Alpha-1
- Prostate cancer and Alpha-1
- Mark's patent overview
What you can do
- Follow oncology guidance for screening and treatment.
- Learn established AATD facts on What is Alpha-1 Antitrypsin Deficiency.
- Discuss AAT testing if you have unexplained lung or liver disease or a family history of AATD.
- Support research funding if you want more independent study of these questions.
Sources and references
References checked July 26, 2026
- Alpha-1 antitrypsin deficiency (MedlinePlus Genetics (NIH))Research status: Established clinical knowledge
- American Thoracic Society / European Respiratory Society statements on lung disease (locate current AATD guidance) (American Thoracic Society)Research status: Established clinical knowledgeUse the current ATS/ERS AATD statements applicable to your practice.
- Method of Preventing and/or Treating a Plurality of Diseases (Mark Egly patent disclosure summary) (Mark Egly Foundation patent overview)Research status: Investigational / hypothesisPrimary source for Mark Egly research hypotheses. Not peer-reviewed clinical evidence. Confirm USPTO application number with counsel before citing externally.
Educational content only. Not a diagnosis or treatment plan. Work with your clinician for personal medical decisions.